Study on the value of combined detection of 6k-PGF1α, CD62P and TXB2 levels in judging the severity of cerebral infarction

Objective To investigate the relationship between the changes of plasma thromboxane B2 (TXB2), 6-keto-prostaglandin 1α (6k-PGF1α) and positive platelet α-granule membrane glycoprotein (CD62P) in patients with acute cerebral infarction. Methods 160 patients with acute cerebral infarction (case group) and 80 healthy subjects were enrolled in our hospital from August 2016 to August 2018. The plasma levels of 6k-PGF1α, CD62P and TXB2 were measured and analyzed. Subgroup analysis was performed on patients with cerebral infarction with different trial of org 10172 in acute stroke treatment (TOAST) classification, National Institute of Health Stroke Scale (NIHSS) score, and prognosis outcome. Results The plasma levels of 6k-PGF1α, CD62P and TXB2 in the case group were significantly higher than those in the control group (P<0.05). The plasma levels of 6k-PGF1α, CD62P and TXB2 in mild, moderate and severe groups were gradually increased (P<0.05). The plasma levels of 6k-PGF1α, CD62P and TXB2 in patients with small infarction, mid-infarction and large infarction were also gradually increased, with statistically significant difference (P<0.05); plasma 6k-PGF1α, CD62P, TXB2 levels in patients with good prognosis were significantly lower than those in poor prognosis group (P<0.05). Conclusions The levels of plasma TXB2, 6k-PGF1α and CD62P in patients with acute cerebral infarction are elevated, and are closely related to the patient's condition and prognosis. Key words: Brain infarction; Thromboxane B2; 6-ketoprostaglandin F1 alpha; Platelet membrane glycoproteins